公开(公告)号：US10900956B2

公开(公告)日：2021-01-26

申请号：US14890578

申请日：2014-05-23

申请人： The Regents of The University of California

发明人： Michael A. Teitell ,  Thomas A. Zangle ,  Owen N. Witte ,  Daina Burnes Linton

IPC分类号： C12N5/00 ,  G01N33/50 ,  G01B9/02 ,  G01B11/06 ,  G02B21/14

摘要： In certain embodiments methods of identifying T cell receptors that respond to specific target cell antigens are provided, where the methods comprise providing a substrate bearing a plurality of target cells (e.g., mammalian cells); contacting the target cells on the substrate with CD8+ T cells; and using label-free optical imaging to identify an increase in mass of a T-cell and/or a decrease in mass of a target cell, where an increase in mass of a T cell and/or a decrease in mass of a target cell is an indicator that said T cell bears a T cell receptor activated by antigens presented on said target cell.

公开(公告)号：US20220308061A1

公开(公告)日：2022-09-29

申请号：US17638092

申请日：2020-09-02

申请人： The Regents of the University of California

发明人： Owen N. Witte ,  Pavlo A. Nesterenko ,  Jami McLaughlin Witte

IPC分类号： G01N33/574 ,  C12Q1/6804 ,  G01N33/569 ,  C12Q1/6806

摘要： The disclosure provides methods and materials useful for obtaining novel TCR gene sequences that are useful in tumor-specific T cell receptor (TCR) gene transfer. Embodiments of the invention also include methods of crosslinking and permeabilizing mammalian cells that can, for example, be used in methods for obtaining novel TCR gene sequences. The disclosure further provides methods and materials useful for obtaining novel TCR gene sequences. Tumor-specific T cell receptor gene transfer enables specific and potent immune targeting of tumor and viral antigens, and for this reason is technology of significant interest to medical personnel.

公开(公告)号：US20210324035A1

公开(公告)日：2021-10-21

申请号：US17273192

申请日：2019-09-04

申请人： The Regents of the University of California ,  California Institute of Technology ,  The Olivia Newton-John Cancer Research Institute

发明人： Owen N. Witte ,  Jami McLaughlin Witte ,  Antoni Ribas ,  Lili Yang ,  Michael T. Bethune ,  Jonathan Cebon ,  Katherine Woods ,  Ashley J. Knights ,  David Baltimore

IPC分类号： C07K14/725 ,  A61K35/17 ,  C12N15/86 ,  C12N5/0783 ,  A61P35/00

摘要： Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.

公开(公告)号：US20160347855A1

公开(公告)日：2016-12-01

申请号：US15181019

申请日：2016-06-13

申请人： The Regents of the University of California ,  Agensys, Inc.

发明人： Robert E. Reiter ,  Owen N. Witte ,  Douglas C. Saffran ,  Aya Jakobovits

IPC分类号： C07K16/30 ,  G01N33/577 ,  A61K51/10 ,  A61K45/06 ,  A61K31/704 ,  G01N33/574 ,  A61K39/395

CPC分类号： C07K16/3069 ,  A01K2217/05 ,  A61K31/704 ,  A61K38/00 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6869 ,  A61K51/106 ,  A61K51/1072 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K16/3038 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/53 ,  G01N33/567 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/577 ,  G01N2333/705 ,  A61K31/00 ,  A61K2300/00

摘要： The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

公开(公告)号：US20140364591A1

公开(公告)日：2014-12-11

申请号：US14297562

申请日：2014-06-05

申请人： The Regents of the University of California ,  Agensys, Inc.

发明人： Robert E. Reiter ,  Owen N. Witte ,  Douglas C. Saffran ,  Aya Jakobovits

IPC分类号： C07K16/30

CPC分类号： C07K16/3069 ,  A01K2217/05 ,  A61K31/704 ,  A61K38/00 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6869 ,  A61K51/106 ,  A61K51/1072 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K16/3038 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/53 ,  G01N33/567 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/577 ,  G01N2333/705 ,  A61K31/00 ,  A61K2300/00

摘要： The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

摘要翻译： 本发明提供了一种新的前列腺细胞表面抗原，其命名为前列腺干细胞抗原（PSCA），其在前列腺癌的所有阶段中广泛过表达，包括高级前列腺上皮内瘤变（PIN），雄激素依赖性和雄激素依赖性 前列腺肿瘤。